These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 26560872)

  • 1. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
    Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
    Weiss TW; Rohla M; Dieplinger B; Domanovits H; Fries D; Vosko MR; Gary T; Ay C
    Wien Med Wochenschr; 2018 Apr; 168(5-6):133-143. PubMed ID: 28236004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban: an update on the new oral direct factor Xa inhibitor.
    Bounameaux H; Camm AJ
    Drugs; 2014 Jul; 74(11):1209-31. PubMed ID: 25034361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.